Can Another Beta-Blocker Be Used?
Yes, a different beta-blocker can be used as an alternative to propranolol in patients with psoriasis, though all beta-blockers carry some risk of exacerbating psoriasis and should be used with caution when cardiovascular indications are compelling.
Evidence-Based Recommendation
The available guidelines clearly identify beta-blockers as drugs that can precipitate or worsen psoriasis 1. However, the evidence suggests this is a class effect rather than specific to propranolol alone, meaning switching to another beta-blocker may not eliminate the risk entirely.
Key Clinical Considerations:
If a beta-blocker is medically necessary:
Beta-1 selective agents (cardioselective) may be preferable to non-selective agents like propranolol. Research suggests different beta-blockers may have distinct pathogenic mechanisms - beta-1 selective agents (metoprolol, atenolol, bisoprolol) appear to cause excessive neutrophil degranulation, while non-selective agents (propranolol, nadolol) trigger macrophage enzyme release 2.
Bisoprolol has been successfully used as an alternative in documented cases of propranolol hypersensitivity 3, though it has also been implicated in triggering psoriasis when combined with immunotherapy 4.
Metoprolol and atenolol are other cardioselective options, though metoprolol has been specifically documented to cause palmar psoriasis 5.
Important Caveats:
The risk-benefit calculation matters critically here:
Recent large-scale epidemiological data suggests the association between beta-blockers and psoriasis may be overstated and confounded by cardiovascular disease itself 6. A 2025 Mendelian randomization study actually found beta-blockers associated with reduced psoriasis risk (OR: 0.9985), suggesting the observed clinical association may reflect confounding rather than causation.
However, individual case reports and clinical experience consistently document psoriasis flares with various beta-blockers 4, 5, 2, 7.
Clinical Algorithm:
Reassess cardiovascular indication: Can the beta-blocker be discontinued entirely? Consider alternative antihypertensives (calcium channel blockers, ACE inhibitors) that don't affect psoriasis.
If beta-blocker is essential: Switch to a cardioselective (beta-1 selective) agent like bisoprolol, metoprolol, or atenolol rather than continuing non-selective propranolol.
Monitor closely: Watch for psoriasis flare over 2-4 weeks after switching. The FDA label for propranolol notes psoriasiform rashes as an adverse effect 8.
Optimize psoriasis management: Ensure aggressive topical therapy or systemic treatment is in place before and during beta-blocker use 1.
Document clearly: If psoriasis worsens with the new beta-blocker, this strengthens the case for using non-beta-blocker alternatives for cardiovascular management.
Bottom Line:
While switching from propranolol to a cardioselective beta-blocker is reasonable and may reduce risk, no beta-blocker can be considered completely safe in psoriasis. The decision should weigh the cardiovascular necessity against dermatologic risk, with preference for non-beta-blocker alternatives when clinically feasible.